Przemyslaw Sapieha is the University of Montreal Endowed Chair in translational vision research, Canada Research Chair in retinal cell biology and director of the Neurovascular Eye Disease Lab at the Maisonneuve-Rosemont Hospital Research Centre. In addition, he is the Chief Scientist at UNITY Biotechnology and Founder and Chief Scientific Officer of SemaThera Inc. His team identified mechanisms implicating deregulation of neuronal metabolism and cellular senescence in retinal vascular diseases such as diabetic retinopathy and age-related macular degeneration (AMD). Notably, they identified roles for guidance cues such as Semaphorins and Netrins in these diseases. His fundamental work has been translated and is currently in distinct clinical trials for diabetic retinal disease and AMD.